Shots.
- The company has submitted MAA to COFEPRIS (the health regulatory authority for Mexico) for its COVI-STIX rapid diagnostic test to detect SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients
- The test provides results in 15min. with positive detection as quickly as 2min for patient samples with high viral load.
- Additionally, Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC and COVI-DROPS and diagnostic test solutions, including COVI-TRACK, COVI-STIX and COVI-TRAC
Click here to read full press release/ article | Ref: Sorrento | Image: Sorrento
The post Sorrento Reports Submission of MAA to COFEPRIS for COVI-STIX Rapid Detection Test first appeared on PharmaShots.
